INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 422m ago
HOUSE PTR21m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Friedberg Ezra M sold PTHS

Director · Pelthos Therapeutics Inc. · Common Stock

Side
SELL
Value
$14K
Shares
534
Price
$26.03
Executed
Jul 2, 2026
Disclosed
Jul 7, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Jul 2 executedJul 7, 2026 disclosed

PTHS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $14K reported value · 0.7% of prior position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PTHS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    PM
    Pauls MatthewDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    786 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    11
    FM
    Friedberg Ezra MDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$12K
    558 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    11
    GP
    Greenleaf PeterDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    797 sh
    		Oct 2, 2026Oct 6, 2026
    traded Oct 2, 2026
    		+4dSEC FORM 4

    Evidence

    17
    FM
    Friedberg Ezra MDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$656
    24 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    17
    GP
    Greenleaf PeterDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    712 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    17
    GP
    Greenleaf PeterDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,318
    85 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    17
    PM
    Pauls MatthewDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$18K
    692 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    17
    PM
    Pauls MatthewDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,572
    94 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    47
    DC
    Davis Todd CDirector
    PTHSPelthos Therapeutics Inc.
    Open-market purchase
    		BUY$986K
    35.4K sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    29
    DC
    Davis Todd CDirector
    PTHSPelthos Therapeutics Inc.
    Open-market purchase
    		BUY$14K
    503 sh
    		Jun 11, 2026Jun 15, 2026
    traded Jun 11, 2026
    		+4dSEC FORM 4

    Evidence

    25
    FK
    Francis Knuettel IICFO, Treas & Secty
    PTHSPelthos Therapeutics Inc.
    Open-market sale
    		SELL$40K
    1,500 sh
    		May 22, 2026May 26, 2026
    traded May 22, 2026
    		+4dSEC FORM 4

    Evidence

    21
    FK
    Francis Knuettel IICFO, Treas & Secty
    PTHSPelthos Therapeutics Inc.
    Disposition to issuer
    		D—
    13.9K sh
    		May 22, 2026May 26, 2026
    traded May 22, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FK
    Francis Knuettel IICFO, Treas & Secty
    PTHSPelthos Therapeutics Inc.
    Grant or award
    		A—
    59.5K sh
    		May 22, 2026May 26, 2026
    traded May 22, 2026
    		+4dSEC FORM 4

    Evidence

    9
    FK
    Francis Knuettel IICFO, Treas & Secty
    PTHSPelthos Therapeutics Inc.
    Disposition to issuer
    		D—
    42.5K sh
    		May 22, 2026May 26, 2026
    traded May 22, 2026
    		+4dSEC FORM 4

    Evidence

    20
    MR
    Malamut RichardDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$5,981
    280 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    FM
    Friedberg Ezra MDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6,010
    293 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    FM
    Friedberg Ezra MDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$5,661
    265 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    PM
    Pauls MatthewDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$8,514
    415 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    PM
    Pauls MatthewDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$7,926
    371 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    20
    GP
    Greenleaf PeterDirector
    PTHSPelthos Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$8,616
    420 sh
    		Apr 2, 2026Apr 6, 2026
    traded Apr 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001919246-26-000102
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jul 2, 2026
    Published
    Jul 7, 2026
    Ingested by INSIDER
    Nov 5, 03:49 UTC
    Last re-read
    Nov 5, 03:49 UTC

    Extracted facts

    Filer
    Friedberg Ezra M
    Role
    Director
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Pelthos Therapeutics Inc.
    Ticker
    PTHS
    Shares
    534
    Price per share
    $26.03
    Value
    $13,900
    Execution date (reported)
    Jul 2, 2026
    Owned after transaction
    81.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    5

    Calculation

    Value = shares × reported price per share

    • Shares: 534
    • Price: $26.0303

    = $13,900

    What this establishes

    Friedberg Ezra M filed this Form 4 reporting a open-market sale of PTHS on Jul 2, 2026. It became public on Jul 7, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Friedberg Ezra Mcik:0001679440
    Issuer
    Pelthos Therapeutics Inc.cik:0001919246

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.